AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Bio-Rad Laboratories Inc (NYSE:BIO)
230.895 USD
-1.525 0.656%Sponsored Reports
Loading...
| Previous Close (in USD) | 232.42 |
|---|---|
| Change | -1.525 0.656% |
| 52 W H/L (in USD) | 387.990/262.120 |
| EBITDA (in USD) | 483.487M |
| PE Ratio | -- |
| Volume | 102317 |
| Diluted Eps TTM | -28.10 |
| Total Assets (in USD) | 12299.07M |
|---|---|
| Total Liabilities (in USD) | 3557.937M |
| Revenue TTM (in USD) | 2580.209M |
| Cash (in USD) | 403.966M |
| Market Cap (in USD) | 9,472.721 M |
| Revenue Per Share TTM | 90.815 |
| Gross Profit TTM (in USD) | 1568.43M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Employees: 7700
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Norman D. Schwartz | Chairman, CEO & Pres | 1950 |
| 2. | Mr. Ilan Daskal | Exec. VP & CFO | 1966 |
| 3. | Dr. Andrew J. Last Ph.D. | Exec. VP & COO | 1960 |
| 4. | Mr. Michael Crowley | Exec. VP of Global Commercial Operations | 1962 |
| 5. | Ms. Dara Grantham Wright | Exec. VP & Pres of Clinical Diagnostics Group | 1976 |
| 6. | Mr. Ajit Ramalingam | Sr. VP & Chief Accounting Officer | 1973 |
| 7. | Mr. Yong Chung | VP of Investor Relations | NA |
| 8. | Mr. Timothy S. Ernst | Exec. VP, Gen. Counsel & Sec. | 1960 |
| 9. | Colleen Corey | Sr. VP of Global HR | NA |
| 10. | Lee Boyd | Sr. VP of Global Commercial Operations - Asia Pacific | NA |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+0.303 0.222% | 135.78 | 37.150 | 23.148 | 4.666 | 4.975 | 4.878 | 19.381 |
|
SYK
Stryker Corporation |
+1.380 0.363% | 377.22 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
-0.314 0.355% | 88.21 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+1.940 1.968% | 98.21 | 68.170 | 24.570 | 5.855 | 4.265 | 6.462 | 26.799 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -4704.273M | 5438.149M | 4907.638M | 2261.081M | 507.359M |
| Minority Interest | - | - | - | - | - |
| Net Income | -3627.535M | 4245.902M | 3806.267M | 1758.675M | 360.996M |
| Selling General Administrative | 827.825M | 879.574M | 800.267M | 824.625M | 834.783M |
| Gross Profit | 1567.33M | 1640.661M | 1437.822M | 1256.996M | 1224.362M |
| Reconciled Depreciation | 137.3M | 133.801M | 138.1M | 134.2M | 138.1M |
| Ebit | 482.616M | 489.43M | 410.957M | 229.661M | 228.465M |
| Ebitda | 664.486M | 650.006M | 573.572M | 389.993M | 366.553M |
| Depreciation And Amortization | 181.87M | 160.576M | 162.615M | 160.332M | 138.088M |
| Operating Income | 482.616M | 489.43M | 410.957M | 229.661M | -108.641M |
| Other Operating Expenses | 2319.633M | 2433.115M | 2134.669M | 2081.998M | 2098.237M |
| Interest Expense | 38.114M | 1.551M | 21.861M | 23.416M | 23.962M |
| Tax Provision | -1076.738M | 1192.247M | 1101.371M | 502.406M | 147.045M |
| Interest Income | 58M | 4921.944M | 4491.393M | 30.5M | 26.6M |
| Net Interest Income | 19.886M | -1.551M | -21.861M | 7.084M | 2.638M |
| Income Tax Expense | -1076.738M | 1192.247M | 1101.371M | 502.406M | 146.363M |
| Total Revenue | 2802.249M | 2922.545M | 2545.626M | 2311.659M | 2290.109M |
| Total Operating Expenses | 1084.714M | 1151.231M | 1026.865M | 1027.335M | 1032.49M |
| Cost Of Revenue | 1234.919M | 1281.884M | 1107.804M | 1054.663M | 1065.747M |
| Total Other Income Expense Net | -5186.889M | 4948.719M | 4496.681M | 2031.42M | 339.449M |
| Net Income From Continuing Ops | -3627.535M | 4245.902M | 3806.267M | 1758.675M | 365.614M |
| Net Income Applicable To Common Shares | -3627.535M | 4245.902M | 3806.267M | 1758.675M | 365.614M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 12299.07M | 13501.666M | 17775.795M | 12972.618M | 8008.859M |
| Intangible Assets | 320.483M | 332.147M | 253.939M | 199.497M | 145.525M |
| Other Current Assets | 171.654M | 147.783M | 117.834M | 101.48M | 113.271M |
| Total Liab | 3557.937M | 3886.414M | 4108.661M | 3092.678M | 2253.802M |
| Total Stockholder Equity | 8741.133M | 9615.252M | 13667.134M | 9879.94M | 5755.057M |
| Other Current Liab | 302.036M | 186.201M | 210.67M | 224.944M | 158.49M |
| Common Stock | 0.003M | 0.003M | 0.003M | 0.003M | 0.003M |
| Capital Stock | 0.003M | 0.003M | 0.003M | 0.003M | 0.003M |
| Retained Earnings | 9260.629M | 9898.203M | 13507.241M | 9268.012M | 5470.779M |
| Good Will | 413.6M | 406.488M | 347.343M | 291.916M | 264.131M |
| Other Assets | - | 94.599M | 0.082M | 0.013M | 40.256M |
| Cash | 403.966M | 434.215M | 470.783M | 662.205M | 660.672M |
| Cash And Equivalents | - | 434.215M | 470.783M | 662.205M | 660.672M |
| Total Current Liabilities | 522.799M | 568.708M | 680.938M | 631.536M | 905.495M |
| Current Deferred Revenue | 35759M | 52.211M | 50.852M | 42.468M | 33.735M |
| Net Debt | 1001.628M | 763.966M | -459.78M | -648.149M | -220.921M |
| Short Term Debt | 40.379M | 0.465M | 0.489M | 1.798M | 426.172M |
| Short Long Term Debt | 0.486M | 0.465M | 0.489M | 1.798M | 426.172M |
| Short Long Term Debt Total | 1405.443M | 1198.181M | 11.003M | 14.056M | 439.751M |
| Other Stockholder Equity | -183.461M | 183.868M | 335.443M | 329.469M | 371.623M |
| Property Plant Equipment | - | 498.612M | 695.75M | 491.371M | 499.339M |
| Total Current Assets | 3048.33M | 3157.976M | 1989.088M | 2139.835M | 2180.155M |
| Long Term Investments | 7698.07M | 8830.892M | 14387.006M | 9561.14M | 4638.205M |
| Short Term Investments | 1203.327M | 1362.017M | 404.695M | 334.473M | 459.533M |
| Net Receivables | 489.017M | 494.645M | 423.537M | 419.424M | 392.672M |
| Long Term Debt | 1199.052M | 1197.716M | 10.514M | 12.258M | 13.579M |
| Inventory | 780.517M | 719.316M | 572.239M | 622.253M | 554.007M |
| Accounts Payable | 144.625M | 329.831M | 418.927M | 362.326M | 287.098M |
| Accumulated Other Comprehensive Income | -336.038M | -466.822M | -175.553M | 282.456M | -87.348M |
| Non Currrent Assets Other | 94.447M | -1770386.401M | -3058977.331M | -2076698.277M | -997707.364M |
| Non Current Assets Total | 9250.74M | 10343.69M | 15786.707M | 10832.783M | 5828.704M |
| Capital Lease Obligations | 205.857M | 189.933M | 212.373M | 211.635M | 211.383M |
| Long Term Debt Total | - | 1197.716M | 10.514M | 12.258M | 13.579M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -110.541M | -994.211M | -538.171M | 119.601M | -119.304M |
| Total Cashflows From Investing Activities | - | -1207.593M | -784.438M | -60.25M | -208.889M |
| Total Cash From Financing Activities | -425.647M | 973.576M | -55.429M | -523.041M | -22.758M |
| Net Income | -637.324M | -3627.535M | 4245.902M | 3806.267M | 1758.675M |
| Change In Cash | -30.175M | -36.589M | -195.982M | 4.464M | 228.487M |
| Begin Period Cash Flow | 434.544M | 471.133M | 667.115M | 662.651M | 434.164M |
| End Period Cash Flow | 404.369M | 434.544M | 471.133M | 667.115M | 662.651M |
| Total Cash From Operating Activities | 374.943M | 194.447M | 656.521M | 575.328M | 457.897M |
| Depreciation | 192.4M | 137.296M | 133.801M | 138.127M | 134.238M |
| Other Cashflows From Investing Activities | - | -100.6M | -658.922M | -80.931M | 0.129M |
| Dividends Paid | 100101M | 68184M | 35282M | 20.198M | 3831M |
| Change To Inventory | -46.3M | -158.8M | 46.1M | -52.1M | 24.2M |
| Sale Purchase Of Stock | -428.728M | -215.679M | -49.998M | -100.004M | -28M |
| Other Cashflows From Financing Activities | 3.548M | -212.134M | -2.411M | 3.901M | 5.885M |
| Capital Expenditures | 156.68M | 114.157M | 120.803M | 98.92M | 98.532M |
| Change In Working Capital | -127.633M | -407.038M | 13.932M | 51.678M | 55.392M |
| Other Non Cash Items | 1078.6M | 5272.424M | -3737.114M | -3420.744M | -1490.408M |
| Free Cash Flow | 218.263M | 80.29M | 535.718M | 476.408M | 359.365M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | VanEck Morningstar Wide Moat | 8 months ago | 1244898 |
| 2. | VanEck Morningstar Wide Moat ETF | 6 months ago | 1237113 |
| 3. | UBS: Global Equity | 11 months ago | 695492 |
| 4. | iShares Core S&P Mid-Cap ETF | 6 months ago | 614879 |
| 5. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 611148 |
| 6. | First Eagle Global A | 7 months ago | 525458 |
| 7. | Vanguard Small Cap Index | 7 months ago | 485931 |
| 8. | Vanguard Small Cap Value Index Inv | 7 months ago | 328279 |
| 9. | Parnassus Value Equity Investor | 7 months ago | 310732 |
| 10. | Parnassus Value Equity Fund Composite | 7 months ago | 310732 |
| 11. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 280599 |
| 12. | EARNEST Partners Smid Cap Core Founders | 6 months ago | 233568 |
| 13. | Veritas Global Focus A USD | 9 months ago | 214244 |
| 14. | Longleaf Partners | 8 months ago | 196969 |
| 15. | DFA US Small Cap Value I | 7 months ago | 183867 |
| 16. | Ariel Fund Investor | 8 months ago | 158609 |
| 17. | FPA Contrarian Value | 11 months ago | 152000 |
| 18. | FPA Crescent | 8 months ago | 152000 |
| 19. | SPDR® S&P MIDCAP 400 ETF Trust | 7 months ago | 150601 |
| 20. | Bellevue Healthcare Ord | 10 months ago | 144062 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 8 months ago | 1907640 |
| 2. | BlackRock Inc | 11 months ago | 1550569 |
| 3. | Van Eck Associates Corporation | 8 months ago | 1303752 |
| 4. | Veritas Asset Management LLP | 8 months ago | 1086479 |
| 5. | Arnhold & S. Bleichroeder Advisers, LLC | 8 months ago | 713000 |
| 6. | Select Equity Group LP | 8 months ago | 708452 |
| 7. | Dimensional Fund Advisors, Inc. | 8 months ago | 654429 |
| 8. | State Street Corp | 8 months ago | 635916 |
| 9. | Earnest Partners LLC | 8 months ago | 605549 |
| 10. | Millennium Management LLC | 8 months ago | 583800 |
| 11. | UBS Asset Mgmt Americas Inc | 8 months ago | 441098 |
| 12. | Ariel Investments, LLC | 8 months ago | 378695 |
| 13. | Geode Capital Management, LLC | 8 months ago | 323908 |
| 14. | Southeastern Asset Management Inc | 8 months ago | 318336 |
| 15. | Parnassus Investments LLC | 8 months ago | 310732 |
| 16. | Thompson, Siegel & Walmsley LLC | 8 months ago | 306793 |
| 17. | Bank of New York Mellon Corp | 8 months ago | 269347 |
| 18. | Westfield Capital Management Company, L.P. | 8 months ago | 252769 |
| 19. | SEI Investments Co | 8 months ago | 252514 |
| 20. | Point72 Asset Management, L.P. | 8 months ago | 250108 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...